1. Volume 68, Issue 4, Pages 621-629 (October 2015)
CYP3A5 and ABCB1 Polymorphisms as Predictors for Sunitinib Outcome in Metastatic Renal Cell Carcinoma 
Meta H.M. Diekstra, Jesse J. Swen, Epie Boven, Daniel Castellano, Hans Gelderblom, Ron H.J. Mathijssen, Cristina Rodríguez-Antona, Jesus García-Donas, Brian I. Rini, Henk-Jan Guchelaar 
European Urology 
Volume 68, Issue 4, Pages (October 2015)
DOI: /j.eururo
Copyright © 2015 European Association of Urology Terms and Conditions

2. Fig. 1
Patient flowchart on included patients. Fifty-nine patients had to be excluded from association analyses because of non–clear cell subtypes (n=38), relocation to another medical centre during follow-up (n=10), individual genotyping call rates <80% (n=9), double patient (n=1), or a change to another treatment than sunitinib directly after enrolment (n=1). A total of 333 sunitinib-treated metastatic renal cell carcinoma patients were available for analysis of toxicity and survival in the present study.
CCF=Cleveland Clinic Foundation; SOGUG=Spanish Oncology Genitourinary Group; SUTOX=Dutch SUTOX consortium.
European Urology  , DOI: ( /j.eururo )
Copyright © 2015 European Association of Urology Terms and Conditions

3. Fig. 2
Multivariate Cox regression analysis for association of genetic polymorphisms in the ABCB1 haplotype (rs , rs , and rs ) with progression-free survival in months, corrected for Heng risk group and study centre.
PD=progressive disease.
European Urology  , DOI: ( /j.eururo )
Copyright © 2015 European Association of Urology Terms and Conditions